Arecor Therapeutics (STU:6UI) Tariff Resilience Score: 0/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6UI Arecor Therapeutics PLC STU:6UI
39 GF Score
Price €0.69
GF Value €0.49
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Tariff Resilience Score?

Arecor Therapeutics has the Tariff Resilience Score of 0, which implies that the company might have .

Arecor Therapeutics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Arecor Therapeutics might have .

Arecor Therapeutics  (STU:6UI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Arecor Therapeutics Tariff Resilience Score Related Terms

STU:6UI
39GF Score
Arecor Therapeutics PLC STU:6UI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.

Key valuation signals for STU:6UI:

  • Tariff Resilience Score: 0
  • GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges AREC:UK
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
39GF Score

Get the complete analysis for STU:6UI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.49
GF Value